| niacin extended-release formulation / Generic mfg. |
NCT00376584: Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED) |
|
|
| Completed | 3 | 825 | NA | MK-0524A, ER Niacin, Placebo | Merck Sharp & Dohme LLC | Hypercholesteremia, Hyperlipidemia | 01/07 | 01/07 | | |
NCT00378833: Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054) |
|
|
| Completed | 3 | 1300 | NA | niacin (+) laropiprant, MK0524A, niacin | Merck Sharp & Dohme LLC | Hypercholesterolemia, Hyperlipidemia | 03/07 | 03/07 | | |
NCT00479388: Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067) |
|
|
| Completed | 3 | 1216 | Canada | Comparator: simvastatin, Zocor®, niacin (+) laropiprant, MK0524A, Comparator: atorvastatin calcium, atorvastatin | Merck Sharp & Dohme LLC | Primary Hypercholesterolemia, Mixed Dyslipidemia | 07/08 | 10/08 | | |
NCT01335997 / 2011-001007-12: Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143) |
|
|
| Terminated | 3 | 1139 | NA | ER niacin/laropiprant (ERN/LRPT), MK-0524B, ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM), MK-0524A, Tredaptive™, Simvastatin (SIM), Zocor®, Placebo Run-In, SIM-matching placebo | Merck Sharp & Dohme LLC | Primary Hypercholesterolemia, Mixed Dyslipidemia | 01/12 | 01/12 | | |
NCT01294683 / 2010-023939-42: A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118) |
|
|
| Terminated | 3 | 977 | NA | Simvastatin, Zocor, Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM), MK-0524B, Extended Release (ER) niacin/laropiprant (N/LRPT), MK-0524A, Placebo | Merck Sharp & Dohme LLC | Primary Hypercholesterolemia, Dyslipidemia | 01/12 | 01/12 | | |
MK-0524A-133, NCT01274559: Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels |
|
|
| Terminated | 3 | 1173 | NA | Extended-release niacin/laropiprant (ERN/LRPT), Placebo | Merck Sharp & Dohme LLC | Primary Hypercholesterolemia, Mixed Dyslipidemia | 02/13 | 02/13 | | |
